NEWSLETTER
RSS
MOBILE
HELP
Vical, Incorporated (VICL)
SHARE
Email Confirmation
OPEN
LAST
$
PREV CLOSE
CHANGE
VOLUME
Overview
News
People
Financials
Company Information
Vijay B. Samant, CEO/President/Director
10390 Pacific Center Court
San Diego, CA 92121-4340
US
Map it 
Overview
The Company is engaged in the research and development of biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases.
Press Releases
-
Vical Announces Strategic Restructuring and Staff Reduction Nov-21-2008, 06:30AM EST
-
Vical Executive Alain Rolland Named AAPS Fellow Nov-17-2008, 06:30AM EST
-
Vical Completes Enrollment and Reports Positive Interim Data in CMV Vaccine Phase 2 Trial Nov-12-2008, 06:30AM EST
-
U.S. Navy and U.S. Army to Develop Dengue DNA Vaccine Formulated With Vical's Vaxfectin(R) Adjuvant Nov-06-2008, 06:30AM EST
News From Around the Web
News
-
SurModics, Vical, and CombinatoRx Lay Off Staff as Part of Restructuring Efforts (Genetic Engineering News)Nov 21 2008
-
Vical Announces Strategic Restructuring and Staff Reduction (Examiner.com: Anchorage, Alaska)Nov 21 2008
-
Nov 21 2008
-
Market Report -- In Play (VICL) (MSN Money)Nov 21 2008
-
Nov 21 2008
-
Vical Commission for $1.3M to Produce Dengue Vaccine and Adjuvant for NMRC’s Evaluation (Genetic Engineering News)Nov 06 2008
-
Vaccine Development Aided by New Techniques (Genetic Engineering News)Nov 03 2008
Employees
Number of Employees: 154
Revenue per Employee: $41,116
Top Executives
Dr.Larry R. Smith, Ph.D., Vice President, Divisional
Jill M. Church, CFO/Vice President/Secretary/Chief Accounting Officer
Dr.Robin M. Jackman, Ph.D., Senior VP, Divisional
Kevin R. Bracken, Vice President, Divisional
Dr.Ronald B. Moss, M.D., Vice President, Divisional
Dr.Alain P. Rolland, Pharm.D., Ph.D., Senior VP, Divisional
Board of Directors
Dr. Robert C. Merton, Ph.D., Director
Jill M. Church, CFO/Vice President/Secretary/Chief Accounting Officer
Gary A. Lyons, Director
Financials
Quarterly
Annual
| Income Statement | 09/2008 | 06/2008 | 03/2008 | 12/2007 |
|---|---|---|---|---|
| Sales | 2.25 Mil. | 2.36 Mil. | -11.8 Mil. | 2.08 Mil. |
| Gross Operating Profit | 301 K. | -425 K. | 12.57 Mil. | -1.71 Mil. |
| Operating Income before D & A (EBITDA) | -8.18 Mil. | -9.35 Mil. | -9.07 Mil. | -9.48 Mil. |
| Total Income Before Interest Expenses (EBIT) | -8.48 Mil. | -9.56 Mil. | -8.85 Mil. | -9.22 Mil. |
| Total Net Income | -8.48 Mil. | -9.56 Mil. | -8.86 Mil. | -9.24 Mil. |
| Basic EPS, Total | -0.21 | -0.24 | -0.23 | -0.24 |
| Diluted EPS, Total | -0.21 | -0.24 | -0.23 | -0.24 |
| BALANCE STATEMENT | 09/2008 | 06/2008 | 03/2008 | 12/2007 |
|---|---|---|---|---|
| Cash and Equivalents | 37.96 Mil. | 38.53 Mil. | 35.35 Mil. | 38.83 Mil. |
| Total Assets | 53.59 Mil. | 53.64 Mil. | 72.75 Mil. | 78.23 Mil. |
| Total Liabilities | 7.57 Mil. | 5.97 Mil. | 8.11 Mil. | 5.77 Mil. |
| Total Capitalization | 66.41 Mil. | 70.55 Mil. | 79.91 Mil. | 88.29 Mil. |
| Cash Flow | 09/2008 | 06/2008 | 03/2008 | 12/2007 |
|---|---|---|---|---|
| Net Cash From Continuing Operations | -16.45 Mil. | -10.34 Mil. | -24.18 Mil. | -19.39 Mil. |
| Net Cash From Investing Activities | 15.47 Mil. | 13.76 Mil. | 42.93 Mil. | 41.11 Mil. |
| Net Cash From Financing Activities | 3.58 Mil. | -242 K. | -2.76 Mil. | -2.26 Mil. |
| Net Change in Cash & Cash Equivalents | 2.61 Mil. | 3.18 Mil. | 15.98 Mil. | 19.46 Mil. |
| Income Statement | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|
| Sales | -3.26 Mil. | -3.28 Mil. | -3.59 Mil. | -3.64 Mil. |
| Gross Operating Profit | 8.78 Mil. | 18.02 Mil. | 15.6 Mil. | 18.18 Mil. |
| Operating Income before D & A (EBITDA) | -37 Mil. | -23.13 Mil. | -22.06 Mil. | -21.51 Mil. |
| Total Income Before Interest Expenses (EBIT) | -35.8 Mil. | -22.88 Mil. | -23.82 Mil. | -22.94 Mil. |
| Total Net Income | -35.89 Mil. | -23.15 Mil. | -24.36 Mil. | -23.73 Mil. |
| Basic EPS, Total | -0.92 | -0.74 | -0.99 | -1.05 |
| Diluted EPS, Total | -0.92 | -0.74 | -0.99 | -1.05 |
| BALANCE STATEMENT | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|
| Cash and Equivalents | 35.35 Mil. | 19.36 Mil. | 5.71 Mil. | 17.67 Mil. |
| Total Assets | 72.75 Mil. | 105.44 Mil. | 72.26 Mil. | 77.41 Mil. |
| Total Liabilities | 8.11 Mil. | 8.15 Mil. | 8.78 Mil. | 10.11 Mil. |
| Total Capitalization | 79.91 Mil. | 114.12 Mil. | 80.31 Mil. | 82.91 Mil. |
| Cash Flow | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|
| Net Cash From Continuing Operations | -24.18 Mil. | -15.67 Mil. | -22.78 Mil. | -21.07 Mil. |
| Net Cash From Investing Activities | 42.93 Mil. | -21.51 Mil. | -6.74 Mil. | 9.79 Mil. |
| Net Cash From Financing Activities | -2.76 Mil. | 50.83 Mil. | 17.56 Mil. | 12.37 Mil. |
| Net Change in Cash & Cash Equivalents | 15.98 Mil. | 13.65 Mil. | -11.96 Mil. | 1.09 Mil. |
Related Companies by Market Cap
Company Name
Price
Change
Market Cap
146.24 Mil.
149.13 Mil.
145.36 Mil.
149.87 Mil.
Company Profile Change Request
The data provided in our company profiles comes from third party information providers.- To request a change please click here
Also in Portfolio.com
Most Read
Most Emailed
Recently Commented
TOP 5
(Daily)
A smart take on the top stories shaping the business world.
Executives & Careers
(Tuesdays)
A weekly guide to the personalities and ideas that are transforming the business world.
Inside Portfolio.com
(Wednesdays)
Our roundup of the week's best from Portfolio.com.
Culture & Lifestyle
(Fridays)
A weekly guide to the best ways to spend your time - and money.
In This Issue
(Monthly)
Be the first to know when the latest issue of Condé Nast Portfolio magazine is online.
RSS Most Read
Mobile